去甲氧柔红霉素和柔红霉素治疗急性髓系白血病的疗效分析

Efficacy of Daunorubicin and Idarubicin in the Treatment of Acute Leukemia

目的比较去甲氧柔红霉素+阿糖胞苷、柔红霉素+阿糖胞苷诱导缓解化疗治疗急性髓系白血病的疗效及安全性。方法选取40例诊断为急性髓系白血病的患者,分为对照组和观察组,每组20例。对照组采用柔红霉素+阿糖胞苷诱导化疗,治疗组采用去甲氧柔红霉素+阿糖胞苷诱导化疗,疗程均为1周。结果比较2组患者的缓解率及不良反应的发生情况。诱导化疗后对照组完全缓解率12例(60%),观察组完全缓解率15例(75%),P<0.05。化疗期间均出现骨髓抑制、感染、出现及胃肠道反应等毒副作用,P>0.05。结论去甲氧柔红霉素+阿糖胞苷是一种治疗急性髓系白血病缓解率高、安全、提高生存率的有效的诱导化疗方案。

Objective To compare the efficacy and safety of idarubicin combined with cytarabine and daunorubicin combined with cytarabine in the treatment of acute myeloid leukemia.Methods 40 patients with acute myeloid leukemia were selected and they were divided into the control group and the observation group,with 20 patients in each group.The control group adopted daunorubicin combined with cytarabine induced chemotherapy,while the treatment group adopted idarubicin combined with cytarabine induced chemotherapy.The treatment cycle was one week.Results The remission rate and the adverse reactions of the two groups were compared.After induction chemotherapy,the total remission rate of the control group was 12(60%),while that of the observation group was 15(75%)(p<0.05).However,during chemotherapy,all patients were found with myelosuppression,infection,gastrointestinal reaction,(p>0.05)etc.Conclusion The combination of idarubicin and cytarabine is an effective chemotherapy regimen for the treatment of acute myeloid leukemia with high remission rate,safety and improvement of survival rate.